Staff members of Sinovac Biotech, a Chinese biopharmaceutical company, pose for a photo in the quality inspection lab in Beijing, capital of China, March 16, 2020. China's National Medical Products Administration (NMPA) on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday. (Xinhua/Zhang Yuwei)
